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BY altering hormonal balance in experimental animals it has been possible to
produce tumours of such organs as the pituitary, thyroid, adrenal, breast, ovary,
uterus and testis (Bielschowsky and Horning, 1.958 ; Gardner, 1948, 1953;
Lacassagne, 1957; Noble, 1957). All these organs are either members of the
endocrine system or else secondary sexual organs which are greatly influenced by
this system. Only rarely have hormonal factors been associated with the develop-
ment and subsequent behaviour of tumours in organs or tissues normally not
under endocrine control. Lymphomas in mice are influenced by oestrogen, the
incidence being increased by this hormone and reduced by ovariectomy or by
androgen administration (Lacassagne, 1938; Dmochowski and Horning, 1940;
(ardner et al., 1940. 1944). The latent period for the development of spontaneous
bone tumours in male mice is reduced by oestrogen administration and prolonged
in females by ovariectomy (Pybus and Miller, 1938; Miller et al., 1943). The
incidence of hepatic tumours in this species is also reduced by oestrogen (Agnew
and Gardner. 1952) anid regression of osteogenic sarcoma and lymphosarcoma can
be brought about by cortisone (Stock, 1952).
In 1944 Vasquez-Lopez noted the presence of a tumour in the kidney of a male
Syrian golden hamster some 300 days after subcutaneous implantation of a
stilboestrol pellet. V'asquez-Lopez regarded the renal lesion as a secondary depo-
sit from either a tumour of the epididymis or the pituitary, both ofwhich were also
present. It was left to Matthews, Kirkman and Bacon (1947) to discover that
the hamster possesses a peculiar susceptability to renal neoplasia in response to
prolonged oestrogen administration. This observation was later confirmed and
extended by Kirkman and Bacon (1949, 1952a, 1952b), Kirkman (1959), Horning
(1952, 1954, 1956a, 195Gb, 1957) and by Horning and Whittick (1954).
The hamster renal tumour is of special interest for three reasons. In the
first instance it is a hormone-dependent tumour which has been readily induced in
an organ which does not belong to the endocrine system and one which is not gener-
ally regarded as coming under the influence of the anterior pituitary gland, other
than the general effects of its growth hormone (Horning, 1.956a). Second, the
hormones concerned with the induction (oestrogens) and prevention (testosterone
and progesterone) ofthis tumour are ofgonadal origin. Finally, ofall observations
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factors are perhaps the most likely to be of value in man, since the principal
action of individual hormones is fundamentally alike in all species.
It is the purpose of this and the following paper (Bloom et al., 1963) to report
experiments concerning the influence of various hormone preparations and of
endocrine ablation procedures on the growth of the transplanted hamster renal
tumour. We will also refer to the influence of various hormones on the normal
kidney and to the role of the kidney as an endocrine organ. Our goal is to draw
attention to the possible application of experimental observations in the hamster
to the endocrine treatment of renal adenocarcinoma in manl. Earlier experi-
mental work with the hamster tumour has been reported in a number of papers
by Dr. Hadley Kirkman and his colleagues from Stanford University, and by the
late Professor Eric Horning from this Laboratory, and also by both these authors
in notes for the Annual Reports of the British Empire Cancer Campaign between
1952 and 1958. Since many pathologists and clinicians are unlikely to be familiar
with the natural history and characteristics of the hamster kidney tumour it has
been deemed worth while to review previous work on the subject before reporting
our owni observations in this field. Particular attention will be given to the mono-
graph published by Kirkman (1959) which appeared soon after the present in-
vestigation had been initiated.
I. REVIEW OF PREVIOUS WORK
Prolonged oestrogen administration to rodents may produce degenerative or
proliferative lesions in the kidney. Such changes have been described in mice
(Selye, 19.39), rats (Pfeiffer et al., 1940; Korenchevsky and Ross, 1940) and in
guinea pigs (Chesterman et al., 1956). The proliferative changes ofthe glomerular
tuft reported in guinea pigs have also been described in men receiving stilboestrol
for prostatic cancer (Trevan, 1956).
The Syrian hamster possesses a peculiar susceptability to oestrogen. In this
animal, and only in the male, the predominant renal lesion produced by pro-
longed administration of stilboestrol is proliferative in type, eventually leading to
the formation of adenomatous tumours. In the intact female such tumours are
not found following oestrogen administration, the chief changes being amyloid
infiltration and tubular atrophy (Matthews et al., 1947).
The experiments carried out by Horning in this Laboratory have shown that,
following subcutaneous implantation of a 20 mg. pellet of diethyl-stilboestrol
in male hamsters 6-8 weeks of age, renal tumours develop and become palpable
within 9-12 months in 70-80 per cent of treated animals. By renewing the pellet
at three to four months tumour incidence can be increased to practicallv 100 per
cent-the lesions are considerably larger, appear earlier and metastasize more
readily.
After approximately seven months the tumours appear as small pale areas
in the renal cortex beneath the capsule. As treatment contiinues they increase in
size and number eventually form multiple, large bilateral tumours showinig
haemorrhagic, necrotic and cystic changes. Although well-defined the tumours
are not truly encapsulated. After nine months the lesions are easily palpable in
the flank of the living animal.
The earliest neoplastic change consists of minute clusters of abnormal cells
in close proximity to the convoluted tubules. The tubular cells increase in size,
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proliferate and obliterate the luminae. Infiltration into the surrounding paren-
chyma occurs and, finally, the fully established tumour consists of compact masses
of pale round cells. Abundant intracytoplasmic doubly refractile lipoid material
is sometimes present producing a vacuolated appearance. Occasionally, tubule
formation is present, but a papillary or pseudo-glandular appearance is more
common.
Histogenesis
Horning and Whittick (1954) considered the hamster kidney tumour to be an
adenocarcinoma arising from proximal convoluted renal tubules. Kirkman and
Robbins (1959) agreed in the main with this view, but believed that the tumour
was also partly of connective tissue origin. Areas of early cellular hyperplasia
produced by prolonged oestrogen administration, although adjacent to renal
tubules, not infrequently appear to be quite separate from them as if arising from
inter-tubular cellular elements.
There is no clear-cut division on histological grounds between simple hyper-
plastic foci, adenoma and carcinoma in the renal parenchyma, all stages of tumour
development being observed, often in the same specimeni.
T'unour spread and netastases
After nine to ten months' treatment with stilboestrol the renal tumour is
likely to have extended beyond the primary site. GCenerally speaking, spread of
these tumours appears to be by direct surface implantation of detached tumour
cells and is confined to the abdominal cavity. Nodules, plaques and sheets of
tumour may be found on the inferior surface of the diaphragm and oni the surface
of the abdominal viscera. Kirkman and Robbins (1959) have reported distant
metastases in cervical lymph nodes and in the lungs. OIn the other hand, Horninig
and Whittick (1954) did not observe distant metastases in anv of their tumour-
bearing animals.
Tumnour transplantation
The presence of excess oestrogen is necessary for the inductioni and sustained
growth of the hamster renal tumour, and also for its survival and further growth
as a transplant. Thus, it is necessary to implant stilboestrol in prospective hosts
three months before the tumour is grafted, if a successful take and subsequent
growth is to be achieved. Initially, a latent period of seven to twelve months
elapsed before the subcutaneous grafted tumours became palpable in the flank of
50 per cent of host animals (Horning, 1956a) but with repeated transfer the
number of successful takes has increased and the latent interval become pro-
gressively shorter.
At the (Chester Beatty Institute the transplantable renal tumour, after re-
maininig depenldent upon continuous oestrogen treatmenit of the host for nearlv
five years of serial grafting, eventually ceased to be dependent upon exogenous
oestrogen administratioin. Kirkman and Horning (1957), whilst working together
also in this Laboratory, reported successful takes of this tumour in 4 of 10 un-
treated male hamsters, but the tumours became palpable only after an average
latent period of 115 months. With each succeeding generation, however, this
interval has steadily decreased and now, after a period of niine years of repeated
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trainsfer, the presenit tumour (forty-fifth generation) becomes palpable in the flank
of practically all animals within two to three weeks of transplantation.
Transplanted experimental tumours which are initially dependent on hormone
pre-treatment of the host for their sustained growth and which subsequentlv
acquire autoniomy, generally arise in endocrine tissues or in secondary sexual
organs. The behaviour of the transplanted hamster renal tumour, although
arising from anl organ which is not a recognized member of the endocrine system,
has much in commoni with such lesions.
Factors Influencing Induction and Growth Rate of the Hamrster Renal Tumour
1. Species and sex
Spontaneous renal tumours are extremely rare in untreated stock hamsters of
either sex. They have not been observed in this Laboratory by Horning and by
the present authors, nor in over 3800 autopsies carried out in Kirkman's depart-
ment (Kirkman, 1957). However, a spontaneous renal adenocarcinoma arising
in a male hamster in 1957 and carried on by serial transplantation has been
reported recently by Fortner et al. (1961).
The hamster renal tumour with which we are concerned is readily induced
by oestrogen only in males. In 268 male hamsters treated with various oestrogen
preparations for 136-659 days renal tumours appeared in 74 per cent of animals
(Kirkman, 1959). This tumour was successfully induced in 450 male hamsters
by Horning (1956b), but the total number of animals treated is not known.
The renal epithelium ofthe female hamster does not readily undergo neoplastic
change following oestrogeni administration. Kirkman (1959) has seen only poorly
developed tumours in one of56 female hamsters following oestrogen administrationl
for periods ranging from 241 to 487 days. Perhaps a more prolonged treatment
with higher doses of oestrogen is necessary to induce tumours in the female. Onl
the other hand, ovariectomy renders the female hamster susceptible to the develop-
ment of this tumour (Kirkman, 1951 ; Kirkman and Wurster, 1957) which was
found in 66 per cenit of 41 castrated females treated with oestrogen (Kirkman,
19t59).
Kirkman (1959) has also been able to produce renal tumours in female hamsters
by manoeuvres other than castration. Thus, by commencing oestrogen admini-
stration within the first few days of life, or by treating new-born animals with
testosterone proprionate before oestrogen administration, it has been possible to
produce tumours in females in whom the ovaries have not been removed.
Tumours of the kidney have only rarely been induced by oestrogen in rodents
other than the hamster. Richardson (1957) reported anl incidence of 2 per cent
among male mice treated with stilboestrol.
2. Type of oestrogen
Most ofthe work oni the hamster renal tumour has been with diethyl-stilboestrol
administered either by injection or as a subcutaneous implant. Oestrone and
oestriol also produce renal tumours, but the latent period with these hormones is
greater than with stilboestrol (Kirkman, 1'959). In earlier experiments Kirkmani
and Bacon (1952b) failed to induce reinal tumours in 12 hamsters with ethyl
oestradiol, but later reported such tumours in 5 of 17 animals treated with this
preparationl (Kirkman, 1959).
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3. I)ose ofoestrogen and duration of treatment
Kirkman an-d Bacon (1952b) found that 0.6 mg. of stilboestrol injected sub-
cutaneously oni alternate days for more than 250 days produced renal tumours
in all of 11 animals, whereas the same amount given every tenth day for 400 days
was quite ineffective. It is to be noted that in the latter case the total amount
of oestrogen administered was only 24 mg. compared with 75 mg. in the more
frequenit treatment. Horning (1956b), who treated his hamsters with sub-
cutaneous pellets of 20 mg. of stilboestrol, found that the incidence, size and(
spread ofinduced renal tumours was increased by a second 20 mg. pellet implanted
:3 to 4 months after the first. By this means the number of successful transplants
was also increased and the latent period shortened.
The duration of oestrogen treatment influences the inductioin of renal tumours.
Thus, Kirkman and Bacon (1952a) found that in 100 animals treated for 250-600
days the tumour incidence was 97 per cent, whereas no such tumours developed
among animals treated for less than 150 days. The observed difference, however,
may have been due to the difference in total dose rather than to durationi of
exposure.
4. Unilateral nuophrecto)y or ureterectomy
Tumours appeared earlier and were larger in the remaining kidney of stil-
boestrol treated hamsters following unilateral nephrectomy (Horning, 1954).
and in the ipsilateral kidney after unilateral ureterectomy (Ising, 1956). In the
former case the mean duration of treatment necessary for tumour inductioni
was 190 days compared with 286 days in unoperated animals. Horning (1954)
suggested that the enhanced effect in his nephrectomised animals was due to
a greater concentration of oestrogenic carcinogen in the remaining kidney, but a
more likely explanation is that a kidney stimulated to hypertrophy is more sensi-
tive to carcinogens than a kidney not subjected to this stress. Kirkman (1959)
repeated Horning's experiment in 12 hamsters, but failed to show any difference
in tumour size compared with 8 intact animals.
5. W'ithdraulal of oestrogen
When oestrogen administration is abruptly withdrawni regressionl of th-ie
-)rimary renal tumour and of transplanted tumour tissue occurs. In such cases
re-implantation of stilboestrol, even after 200 days, is followed by tumour re-
generation and regrowth (Kirkman, 1959). There is some evidence from endo-
crine ablation experiments with replacement therapy described in our sub-
sequenit paper (Bloom et al., 1963) which suggests that the transplanted tumour.
when deprived of stilboestrol, may remaini under the influence of endogenous
oestrogen from such organs as the testes or adrenals. These glands may be res-
ponsible for maintaining tumour viability over long periods following withdrawal
of administered oestrogen.
i. Administration ofchemnical carcinogens
(i) 20-Methylcholanthrene.-Implantation of this carciniogeni in male hamsters
treated with diethyl-stilboestrol reduced the incidence and growth rate of relnal
tumours. Small cortical tumours were present in only 20 per cent of ainimals
treated in this way compared withl multiple large tumours in over 80 per cent of
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animals treated solely with stilboestrol (Kirkman and Horning, 1957). Haddow
(1947) has shown that chemical carcinogens may produce an inhibitory effect on
tumour and general body growth.
(ii) 3,4-Benzopyrene. Subcutaneous treatment with this agent induced two
renal cortical tumours in 15 male hamsters (Horning, 1954). It is of interest that
this carcinogen possesses weak oestrogenic activity (Cook and Dodds, 1933).
7. Admninistration of iarious hormones
(i) Testosterone.-Testosterone proprionate, in doses of up to 2-5 mg. sub-
cutaneously once weekly, to young male hamsters implanted with 20 mg. of
stilboestrol prevented the development of renal tumours (Horning, 1956b).
Kirkman (1959) also found that the addition oftestosterone to oestrogen inhibited
the induction of this tumour, but noted a more rapid growth in the case of the
established primary or the transplanted tumour.
(ii) Progesterone. Horning (personal communication, 1959) had observed a
possible inhibitory effect on the transplanted oestrogen dependent renal tumour
with a progestational agent, 6-alpha-methyl-17-alpha-hydroxyprogesterone ace-
tate (Provera) (Babcock et al., 1958). Later in the same year Kirkman (1959)
reported that renal tumours failed to develop in 11 intact male hamsters treated
with combined implants of stilboestrol and progesterone for 293-452 days. In
7 other stilboestrol-treated animals the growth rate of transplanted renal tumour
tissue was reduced by progesterone administration.
(iii) Corticosteroids: (a) 1)eoxycorticosterone acetate. This hormone im-
planted in 11 stilboestrol-treated male hamsters inhibited the induction of renal
tumours, except in one animal which showed microscopic nodules in the kidney.
In 9 oestrogen-treated hosts bearing transplanted tumours deoxycorticosterone
acetate brought about some reduction in growth rate of the graft compared
with stilboestrol treated controls (Kirkman, 1959).
(b) Cortisone. In 8 oestrogen-treated male hamsters bearing transplants
of oestrogen-induced renal tumours Kirkman (1959) found that the addition of
cortisone to stilboestrol appeared to increase the incidence of primary renal ham-
ster tumours and of metastases.
To summarise testosterone, progesterone or deoxycorticosterone acetate
when administered to stilboestrol-treated male hamsters inhibited the induction
of renal tumours. In the case of the transplanted tumour, progesterone and
deoxycorticosterone acetate each reduced growth rate whereas testosterone
appeared to accelerate it. This influence of sex hormones on a tumour of renal
origin is of great interest, the kidney not being a recognized member of the
endocrine system not a secondary sex organ.
Mechanism of Tuamour Induction by Stilboestrol in the Hamster Kidney
The mechanism of renal tumour induction by oestrogens is unknown. Pro-
longed administration of stilboestrol to the hamster also produced tumours of
the pituitary pars intermedia in 65 per cent of animals (Horning, 1956b). At one
time Horning (1955) planned to study the effect of pituitary ablation on the
development of the oestrogen--induced renal tumour. Kirkman (1957) stated
without giving details, that renal tumours could be induced by oestrogen in
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hypophysectomised animals and that they could be successfully transplanted
in oestrogen-treated hypophysectomised hosts. This suggests that oestrogen
may act directly on renal tissue and that an indirect action via the pituitary gland
is unlikely. More recently, Kirkman (1959) referred to 4 hypophysectomised
hamsters treated with stilboestrol, all ofwhich developed bilateral renal tumours.
Ghaleb (1961), working in this Institute, with tritium-labelled diethyl-stil-
boestrol, found further evidence for a direct carcinogenic action of oestrogen on
the hamster renal epithelium. The tracer hormone was taken up and bound to
renal cellular proteins. In view of the sex-linked liability to develop renal tum-
ours it was interesting to find that the renal epithelium of the male hamster
concentrated twice the amount of labelled oestrogen compared with that of the
female. Ghaleb suggested a possible relationship between renal carcinogenesis
in the hamster and the binding of stilboestrol to kidney cellular proteins. On the
other hand, Kirkman (1959) assumed that no fundamental difference existed be-
tween kidney tissue in male and female hamsters with regard to stilboestrol
carcinogenesis, since tumours were found in fragments of renal tissue which had
been taken from new-borin male or female donors and transplanted into stil-
boestrol-treated male hosts.
II. PRESENT INVESTIGATION
Small renal adenomas are a common finding at routine human autopsy,
especially in men over age forty with nephrosclerosis. In such cases it is possible
that cholesterol is a stimulant to tubular proliferation. Leary (1950) has des-
cribed a sequence of events from the deposition of cholesterol ester crystals in
renal epithelial cells to the formation ofadenomatous tumours. There is no clear-
cut divisioni oIn histological grounds between adenoma and adenocarcinoma of
low grade malignancy in the human kidney (Cristol et al., 1946 ; Willis, 1948
Griffiths and Thackray, 1949), all gradations between a benign lesion and a carci-
noma of high malignancy being seen. It is likely that at least some carcinomas
of the kidney in man arise from these early adenomatous lesions (Trinkle, 1936;
Newcombe, 1937): the small foci seen at routine autopsy may represent latent or
pre-invasive malignant tumours, a position comparable to that described in the
prostate by Franks (1954; 1956) and possibly in other sites such as thyroid,
breast and adrenal. The cause of latency in such tumours is unknown, but it is
likely that hormonal environment in the host is involved.
The natural history of adenocarcinoma of the human kidney also suggests
the possibility of this tumour being under hormonal influence. Thus, the very
slow progress of some primary and metastatic tumours, the long interval which
may occur between nephrectomy and the appearance of distant metastases,
the examples of spontaneous regression and those rare cases of prolonged survival
or apparent cure following removal of a solitarv deposit suggest that in such cases
the tumour is not completely autonomous.
Hormones and the Normnal Kidney
In view of the observations concerning the oestrogen-induced renal cortical
tumour in the hamster and the suggestion that adenomatous tumours ofthe human
kidney may be influenced by the endocrine system, it is relevant to consider
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possible effects of this system on the normal kidney with special reference to
hormones of gonadal origin.
The kidney is a target organ for posterior pituitary anti-diuretic hormone and
for adrenal cortico-steroids which control water and salt excretion respectively.
The anterior pituitary influences renal structure, probably by virtue of its growth
hormone. Thus, in experimental animals hypophysectomy causes renal atrophy
(Selye, 1941) and prevents the compensatory hypertrophy of the remaining
kidney following unilateral nephrectomy (Winternitz and Waters, 1940; McQueen-
Williams and Thompson, 1940). Administration of crude anterior pituitary ex-
tracts to hypophysectomized rats restores kidney weight (Selye, 1941) and pre-
prevents the atrophy which follows unilateral ureteric ligation (Selye and Hollett,
1945).
It has been known for thirty years that gonadal hormones influence the
kidnev in certain experimental animals. Thus, gonadectomy reduces kidney
weight in male rats, and androgens induce renal hypertrophy in normal and
ovariectomized female rats and in castrated males (Korenchevsky et al., 1,933a,
1933b; Korenchevsky and Dennison, 1934, 1935; Korenchevsky and Ross,
1940). Selye (1939) found that androgens enlarge the kidneys in both intact and
castrated mice of both sexes. These hormones increase the compensatory
hypertrophy of the remaining kidney following unilateral nephrectomy (Mackay,
1940; Lattimer, 1942) and protect the kidney from atrophy caused by ureteric
ligation (Selye and Friedman, 1941). Oestrogens, on the other hand, were found
to produce essentially degenerative changes in the rat and mouse kidney (Koren-
chevsky and Ross, 1940: Selye, 1939). Ludden et al. (1941) found an increase in
kidney weight in rats treated with oestradiol benzoate, but this was attributed to
water retention in the renal tissue. On the other hand, Shimkin et al (1963) have
recently reported experiments in male mice of the ACLB and C3H strains in
which oestrogen produced a rapid and sharp drop in kidney weight. There was
some evidence that a direct hormonal effect on the kidney itself was responsible
for these changes. Histological examination did not reveal any abnormality,
and it was postulated that the weight increase was related to a disturbed electro-
lyte-water balance.
The chief histological changes produced in the kidney by androgens are hyper-
trophy of the convoluted tubules and of the parietal cells of Bowman's capsule
(Selye, 1939). These changes are essentially an exaggeration of the normal sex
difference in the renal architecture of most strains of mice. The changes in
13owman's capsule may also be induced by pregnancy (Crabtree, 1941).
Progesterone also caused an increase in kidney weight when administered to
mice and rats of either sex (Selye and Stevenson, 1940; Selye, 1940). This effect
was antagonistic to the weight-depressant action of oestrogens.
The renotropic action of testosterone and of progesterone is probably a direct
one since these hormones exert kidney-stimulating effect in the hypophysecto-
mized rat (Selye, 1941).
Fishman (1951) and Fishman and Farmelant (1953) have shown that the
concentration of glucoronidase in the mouse kidney is selectively increased by
testosterone treatment. This action appears to be specific for androgens as
distinct from oestrogens, progesterones and cortico-steroids and is nullified by
stilboestrol (Fishman et al., 1955).
Although the principal effect of various hormones is essentially the same in all
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species the changes produced by gonadal hormones on the kidney are not com-
parable in all experimental animals. Thus, in contrast to the findings in mice
and rats neither castration nor androgen administration produced an appreciable
increase in kidney weight in the hamster, although the concentration of renal
enzymes in this animal was altered by these procedures (Kochakian et al., 1948).
The kidney itself appears to fulfil the role of an endocrine organ. It is the
site of production of " angiotensin " which is regarded as a renal hormone con-
cerned with the control ofblood pressure and blood distribution (Page and Bumpus,
1960). More recently, investigations have indicated that the kidney may also
be involved in the control of red blood cell formation, and the site of production
of " erythropoietin " (Jacobson et al., 1957 ; Naets, 1958; Gurney et at., 1960;
Plzak, 1960). The occasional association of adenocarcinoma of the kidney with
polycythaemia (Conley et at., 1957; DeWeerd and Hagedorn, 1959) provides a
possible link between tumours arising from the human renal cortex and hormone
activity. With removal of the tumour the blood picture returns to normal:
with the development of metastases the polycythaemic picture may be re-estab-
lished. Hewlett et al. (1960) have found increased amounts of erythropoietin in
extracts prepared from renal adenocarcinoma in polycythaemic patients.
Erythropoietin production by the kidney appears to be under pituitary
control, hypophysectomy in the experimental animal being followed by severe
anaemia and interference with the erythropoietic response to anoxia (Van Dyke
et al., 1954).
All these facts suggest that the relationship between hormones and the normal
kidney is much greater than is perhaps generally appreciated. The question we
seek to answer is whether this endocrine influence extends to tumours of renal
origin, to adenocarcinoma of the kidney in man. This concept, together with
the observations on renal tumour production by stilboestrol in hamsters prompted
one of us, early in 1959, to consider hormone therapy for patients with metastatic
adenocarcinoma of the kidney (Bloom, 1960). At that time Professor Horning
had commenced some preliminary observations on the effect of the progestational
agent, Provera, on hamster renal tumours. Although his results were incon-
clusive he thought that this substance might exert some degree ofinhibition on the
transplanted dependent renal tumour.
It was decided to try Provera in human renal cancer. In May 1959 a very
ill woman aged 28 with abdominal metastases was treated with this preparation,
but no objective response was observed and the patient died within three months.
A second patient, a man of 64 with pulmonary and skeletal metastases, com-
menced Provera in August 1959 and within five weeks there were radiological
signs of regression of the pulmonary metastases. Since then several other cases
have been treated with Provera and also other hormones, and this experience
will form the subject of a separate clinical report in collaboration with Mr. D. M.
Wallace.
In October 1959 H.J.G.B. hoped to collaborate with Horning in some further
animal experiments to test various hormones against the hamster tumour with
the aim of applying such observations to the treatment of human renal adeno-
carcinoma, but Horning died on November 14th before the meeting to plan these
experiments could take place. In January 1960 the present team came together
and, whilst the clinical observations continued, the following animal experiments
were undertaken.
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EXPERIMENTS
Since it requires some nine months to induce palpable renal tumours in
the hamster with stilboestrol it was decided to investigate the influence ofhormone
administration on the transplanted tumour which was available for immediate
use. This tumour, in its twentieth generation and independent of stilboestrol
administration to the host, gave a high percentage of successful takes and formed
a palpable nodule in the subcutaneous tissue, 8-10 mm. in diameter, within 2-3
weeks of transplantation.
1. Horinones Studied
(a) Provera
Compared with oestrogens and androgens, progesterone and progesterone-like
substances have received little attention in relation to experimental and human
tumour growth. The reports available regarding the action of progesterone oln
tumour development are often contradictory, but in general this hormone has an
antagonistic effect on experimental oestrogen-induced tumours such as mammary
growths in rats, (Noble and Collip, 1941 ; Heiman, 1943) and abdominal fibro-
mvomas in guinea pigs (Lipschutz et al., 1939).
It is interesting to recall that Selye and Stevensoin (1940) and Selye (1941)
found that progesterone had a direct effect on the normal kidney ofthe mouse and
rat. Kirkman (1959) reported that this hormone inhibited the development of
the adenomatous renal tumour in oestrogen-treated male hamsters.
At the time of planning our experiments there were few reports concerning
the use of progesterones for human cancer. These indicated a possible effect
in carcinoma of the prostate (Trunnell et al., 1951) and breast (Gorden et al.,
1952). Further reports subsequently appeared concerning progesterones in the
treatment of breast cancer (Goldenberg and Hayes, 1959 ; Yolk et al., 1960;
Jonsson et al., 1959) and carcinoma of the endometrium (Kelly and Baker, 1961),
and these are ofspecial interest in view ofthe known relationship ofthese tumours
to oestrogen.
Provera, the trade name for 6-alpha-methyl-17-alpha-hydroxyprogesterone
acetate (Babcock et al., 1958), was the progestational agent chosen for both our
hamster experiments and clinical studies, primarily because of the preliminary
observation made by Horning (personal communication) in a small number of
animals that this substance appeared to inhibit the transplanted oestrogen-
dependent renal tumour. This preparation also appeared to be the most active
progestational agent known, possessing a high degree of oral efficiency with no
or very little androgenic and oestrogenic properties. It is considered to be 50-60
times more active than ordinary progesterone on subcutaneous administration,
and 100-300 times more active than ethisterone when taken orally (Babcock et al.,
1958).
Provera has a very low toxicity even in high dosage. Single doses of up to
10,000 mg./kg. orally, and repeated doses of 30 mg./kg. daily for 190 days failed
to produce any toxic effects in rats. The LD50 single dose intravenously for mice
was 376 mg./kg. (Upjohn Ltd., personal communication). In more recent experi-
ments in this laboratory in collaboration with Dr. F. J. C. Roe, Provera was
administered subcutaneously in doses of 20-40 mg. daily for 27 days to hamsters
weighing 90-110 g. These animals remained generally well, but lost an average
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7 per cent of their original weight with the lower dose and 20 per cent with the
higher dose.
(b) Testosterone
Androgens have also been employed as antagonists to the neoplastic pro-
perties of oestrogen. Thus, in the mammary fibroadenoma of mice and rats
testosterone decreases the number of successful transplants and reduces growth
rate of established lesions (Heiman, 1940a, 1940b, 1940c, 1943 ; Huggins et al.
1956). Testosterone proprionate inhibits the development of oestrogen-induced
uterine and abdominal fibroids in the guinea-pig (Lipschutz and Vargas, 1941)
and opposes the leukaemic action of oestrogen in mice (Gardner et al., 1944).
Oestrogens have a role in experimental mammary carcinogenesis and in human
breast cancer, and in both these fields testosterone has an inhibitory action.
We have already referred to the fact that androgens may act on the normal
kidney of certain experimental animals, especially the mouse and rat, leading to
an increase in weight of this organ due to hypertrophy and hyperplasia of the
convoluted tubules.
Horning (1956b) in this Laboratory found that testosterone proprionate in-
hibited induction of the hamster renal tumour by stilboestrol. Kirkman (1959)
confirmed this finding with the induced primary tumour, but observed a possible
stimulating effect in the case of the oestrogen-dependent transplant.
(c) Cortisone
In recent years many observations have been made on the effect of cortisone
and related compounds on the growth and dissemination of spontaneous and
transplanted tumours in various laboratory animals.
Transplanted malignant lymphomas including leukaemic cells are markedly
inhibited by cortisone in the mouse and rat (Heilman and Kendall, 1944; Murphy
and Sturm, 1944; Burchenal et al., 1950; Ingle and Nezamis, 1951 ; Lampkin
and Potter, 1958). A less marked effect with large doses of this hormone has
been reported in certain non-lymphomatous transplanted and spontaneous tum-
ours (Stock and Suguira, 1958; Higgins et al., 1950; Suguira et al., 1950; Gotts-
chalk and Grollman, 1952; Baserga and Shubik, 1954; Sparks et al., 1955;
MacAlpine et al., 1958).
With large doses of cortisone it is possible to reduce the growth rate and
induce areas of massive necrosis in certain experimental tumours. The extent
of tumour destruction varies from 25 to 90 per cent: complete destruction is
never seen. The doses of cortisone required to bring about marked tumour
changes also induce inflammatory and degenerative lesions in vital organs such
as the lungs, liver and kidney. The treated animals become ill and die, not from
the tumour but from hormone treatment. The addition of0-1 per cent terramycin
to the drinking water reduces the side-effects of cortisone without interfering with
its tumour inhibitory action (Martinez et al., 1952).
Cortisone has been used in the treatment of a wide variety of malignant
tumours, but it is only in patients with acute leukaemia, lymphosarcoma and
chronic lymphatic leukaemia that temporary regression is to be expected with
this hormone. Occasionally, objective signs of improvement may occur in
breast cancer (Lemon, 1957, 1959; Pearson et al., 1955) and in prostatic cancer
(Huggins et al., 1953; Taylor et al., 1950).
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Tumour inhibition by cortisone has been reported in the hamster by Lemon
and Smakula (1955) who studied a transplanted methylcholanthrene-induced
sarcoma, and by Crabb and Kelsall (1951) in a transplanted mixed cell sarcoma of
the lung. The doses of cortisone employed by Lemon and Smakula (1955) were
also toxic for the host. Kirkman (1957) mentioned that deoxycorticosterone
prevented renal tumour induction by oestrogen in male hamsters and that corti-
sone had no such effect. In a later paper Kirkman (1959) reported inhibition
of renal tumour induction in 10 of 11 stilboestrol-treated animals using deoxy-
corticosterone as a 20 mg. subcutaneous implant. This hormone also reduced
growth rate ofthe transplanted oestrogen-dependent tumour in 7 animals studied.
Cortisone, on the other hand, appeared to increase the incidence of primary
renal tumours and of metastases in stilboestrol-treated hamsters already bearing
renal tumour transplants.
The structure and function of the normal kidney are influenced by adrenal
corticosteroids. Moderate doses of these steroids in, for example, the rat produce
renal hypertrophy (Selye, 1940; Ludden et al., 1941) whilst toxic doses cause
marked degenerative changes (Selye, 1950).
(2) Method
The present experiments were conducted with nmale Syrian golden hamsters
aged 12-16 weeks and weighing 90-110 g. which were bred in the laboratories of
the Chester Beatty Research Institute. The 21st to 32nd generations of trans-
planted renal tumour, independent of oestrogen administration, were employed.
Under general ether anaesthesia a fragment of tumour approximately 5 mm. in
diameter was implanted subcutaneously by trocar into the animals' flank. In
two to three weeks the tumour became palpable as a nodule some 8-10 mm.
in diameter. Tumour size was determined daily by careful caliper measurement
and expressed as the sum of two diameters. In the treated animals hormone
administration was commenced three to four days after the tumour was easily
palpable. Each hormone was given subcutaneously and usually three times
weekly. The doses employed were well above physiological levels, being based
on quantities in excess of those used for tumour treatment in man.
The hamsters were kept five in a cage, fed on a routine diet consisting of
maize, sun-flower seeds, rat cake and peanuts, and maintained at room tempera-
ture. The animals were all killed after a period of observation or, in the case of
the more prolonged experiments, only when the enlarging tumour became a
burden to the host, or if the animal became ill from treatment. Post-mortem
examinations were performed and tumour tissue and relevant organs taken for
histological study.
(3) Procedures
Experiment I
The following animal groups were studied.
Group 1. 6 control animals (transplanted tumours untreated with hormones).
Group 2. Provera (Upjohn Ltd.), 2-5 mg. twice weekly subcutaneously to 6
animals from day 20 following tumour transplantation.
Group 3. Cortisone (Rousell), 2-5 mg. daily subcutaneously Monday to Friday
each week to 6 animals from day 20.
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Groutp 4. Testosterone proprionate (Schering) 2*5 mg. twice weekly subcuta-
nieously to 6 animals from day 20.
Results.-Tumour grafts were successful in all 24 animals. By day 30 following
transplantation it was evident that the tumours of the animals receiving Prover--.
or testosterone were comparable to the control tnmonrs in the untreated animals.
On the other hand, marked inhibition of tumour growth occurred in all animals
treated with cortisone (Fig. 1-3). In one of the animals the tumour, after becom-
'1 ranisplanited Indepenidenit Renial Tumour in Male Hamsters - (Experiment I)
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ing palpable, disappeared by day 21 and failed to reappear by day 41 : actual
tumour regression was not observed in the remaining 5 animals treated with this
hormone. The hamsters receiving cortisone became ill and two died on day 41 :
the remaining 4 animals in this group were killed between day 43 and 49. The
control animals and those receiving testosterone remained generally well and were
destroyed only when their tumours became a burden between day 42 and 49.
On day 42 the 6 animals receiving Provera were divided into two groups.
In 3 animals, bearing the largest tumours, Provera was replaced by cortisone
Tranisplanted Inidependenit Renal Tumour in Male Hamisters - (Experiment I)
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to see whether a well-established tumour could be influenced by this hormone.
The remaining 3 animals continued on Provera as controls. In view of the
toxic effects noted with 2*5 mg. cortisone daily this dose was given only three times
weekly. The tumours in the Provera treated hamsters continued to grow well,
but in the animals receiving cortisone there was marked tumour inhibition and
some regression took place (Fig. 4). On the reduced dosage of cortisone, toxicity
was less marked and 2 animals were allowed to continue to day 58 and one to day
87.
Tranisplanited Inidepenident Renal Tumour in Male Hamsters - (Experiment I)
EFFECT OF CORTISONE IN 6 ANIMALS
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Experiment II
Group 1. 6 control animals (transplanted tumours untreated with hormones).
Group 2. Cortisone, 2.5 mg. three times weekly to 6 animals from day 21
when the transplanted tumours were palpable.
Group 3. Cortisone, 1.25 mg. three times weekly to 6 animals from day 21
when the tumours were palpable.
Transplanted Independent Renal Tumnour in Male Hamsters - (Experiment I)
EFFECT OF PROVERA ALONE, AND OF CORTISONE AFTER PROVERA
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FIGe. 4.-Progressive tumour growth in 6 animals treated with Provera. Inhibition and
some regression in well-established neoplasms when Provera was replaced by cortisone
administration in 3 animals.
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Group 4. Cortisone, 2-5 mg. three times weekly to 6 animals from day 28
when the tumours were well-established and ofmoderate size.
Results.-The tumour grafts were successful in all 24 animals and those in the
control group grew rapidly (group 1 in Fig. 5). The animals treated with cortisone
from day 21 following transplantation all showed prompt tumour inhibition, a
greater effect being observed at the higher dose level. In animals treated with
cortisonie after the tumour had reached a moderate size, inhibition of further
Traisplanitecd Independent Renial Tumour in Male Hamsters - (Experiment II)
EFFECT OF CORTISONE
Tumiioutr size. (Mealn of two diameters)
nin .
loor
1 - Controls (6 aniimals)
2 -- Cortisone 2. 5 mg. x 3/week (6)
3 -- Cortisone 1- 25 mg. x 3/week(6)
4 -- Cortisone 2. 5 mg. x 3/week (6)
(Well established tumour)
3
2
0 10 20 I~~~~
Transplants. Cortisonie
commenced
in groups
2 & 3
t30
Cortisone
commence
in group
40 50 60 70 80 90 100
Days
4
FIG. 5.-Degree of tumour inhibition with cortisone varied with dose. Large tumours as
well as small lesions affected by this hormone.
90
80
70
60
50
40
30
20[
lo0
I1628 H. J. G. BLOOM, C. E. DUKES AND B. C. V. MITCHLEY
growth occurred and some regression was also noted. The experiment was
terminated on day 50.
Experiment III
Group 1. 6 control animals (transplanted tumours untreated with hormones).
Group 2. Cortisone, 125 mg. three times weekly to 6 animals from day 18
to 49.
Group 3. Cortisone, 1*25 mg. three times weekly to 6 animals from day 18
to 78 following transplantation.
Transplanted Independent Renal Tumour in Male Hamsters - (Experiment III)
EFFECT OF CORTISONE ALONE AND OF CORTISONE + PROVERA
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Group 4. Cortisone, 125 mg. together with Provera 2-5 mg. three times
weekly to 6 animals from day 20 to 40.
Results. Tumour grafts were successful in all 30 hamsters. In the controls
rapid sustained tumour growth occurred which necessitated killing the animals
on day 40 (group 1 in Fig. 6). Cortisone reduced tumour growth rate which,
however, resumed its original pattern when the hormone was suspended on day 49.
The most striking effect was produced by the combination of cortisone and
Provera which resulted in almost complete tumour inhibition (group 4 in Fig. 6).
Five of the 6 animals treated by these two hormones showed no evidence of
tumour growth beyond the palpable stage. In the remaining animal only very
slight growth took place. The hamsters treated with cortisone and Provera
all showed signis of general toxicity by day 38 and the experiment was terminated
on day 40.
Inhibitioni of the hamster renal tumour by cortisone may be due to a specific
aniti-tumour effect, or to a more general inihibitory action oni tumours in this species.
Aniother possible explanation is that the doses of cortisone employed in these
experiments were toxic and tumour inhibitioni was merely secondary to somatic
disturbanice in the host. Experiments IV-VII were undertaken to study these
questions.
Experiment IfV
Cortisone toxicity test.
Group 1. Cortisone, 2-5 mg. subcutaneously three times weekly to 5 non-
tumour bearing male hamsters for 37 days.
Group 2. Cortisone, 1-25 mg. subcutaneously three times weekly to 5 animals
similar to those in group 1 for 37 days.
Group 3. Liberal diet of routine food-stuff (10 g. daily) to each of 5 animals
bearing transplanted renal tumours for 43 days.
Group 4. Restricted diet of similar food (5 g. daily) to each of 5 animals
bearing transplanted renal tumours for 43 days.
Results. The cortisone-treated animals appeared to remain generally well,
but those receiving the higher dose (group 1) lost weight, the average at the end
of the experiment being 103 g. compared with III g. before treatment (Fig. 7a).
During this time hamsters of the same strain and age and kept on the same diet
without treatment would be expected to increase their weight by approximately
5 per cent. The weight of the animals on the lower dose of cortisone (group 2)
remained stationary (Fig. 7a). The carcass weight of 3 of the 5 tumour-bearing
animals receiving the liberal diet (group 3) was between 10-19 per cent lower than
the original body weight; in 2 animals the weight had increased by 2 and 11 per
cent respectively. The tumours of all these 5 animals grew well. The carcasses
of the animals on a restricted diet (group 4) had lost between 14 and 30 per cent
(average 23 per cent) of the original body weight. The growth rate and the
final diameters of their tumours was approximately 20 per cent less than in the
control animals receiving the liberal diet. Increasing tumour size in the presence
of a rising or falling animal weight is shown in Fig. 7b.
It is concluded that the marked tumour inhibition observed in our experiments
with cortisone treatment cannot be explained by non-specific effects of cortisone
on body weight. Sparks et al. (1955) also tried to evaluate the anti-tumour effect
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of cortisone in the presence of general weight loss in C3H mice bearing tranis-
planted mammary tumours: the administration of pituitary growth hormone
(S.T.H.) with cortisone prevented body weight loss, but not tumour inhibition.
In order to try and determine whether the cortisone inhibition of the trans-
planted renal tumour in the hamster was due entirely to a non-specific tumour
CORTISONE TOXICITY TEST - (EXPERIMENT IV)
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FIG. 7(a).
FIG. 7a and b.-Cortisone toxicity test and effect ofrestricted diet on body weight and tumour
size: hamsters treated with these doses of cortisone remained generally well, but at the
high level there was some loss ofbody weight. In animals on a restricted diet well-marked
tumour growth occurred in spite of loss of body weight.
effect in this species, a renal tumour of different aetiology and also two unrelated
tumours arising from other tissues were studied for cortisone inhibition (experi-
ments V, VI and VII).
Experiment V
The tumour in this experiment was the transplantable soft tissue sarcoma C.B.
4460 which was originally induced in hamsters treated in the Chester Beatty
40 1 a T I v I I I I I I I I 9 I a
630HORMONE-DEPENDENT TUMOURS OF THE KIDNEY 631
Research Institute with an iron-dextran preparation (" Imferon ") and which was
now in its twenty-second generation. This tumour gives a high proportion of
successful takes and grows rapidly.
Group 1. 6 control animals (transplanted tumours untreated with hormones).
Group 2. Cortisone, 1.25 mg. three times weekly to 6 animals from day 7
following transplantation.
EFFECT OF DIET ON BODY WEIGHT AND TUMOUR SIZE (EXPERIMENT IV)
Body weight/ Tumour size in mm.
in Prammps/ (Mean of two] diameters) _------- 3
o_~~~~d
4
3
/ / /
/
/
~~~~//
4
/s / ~3. - -- Average weight of 5 hamsters bearing
"}'~~~~~ ~ transplanted tumours and receiving
liberal diet.
0-1//~ ~3.---- Average tumour size in this group.
4. Average weight of 5 hamsters bearing
transplanted tumours and receiving a
restricted diet.
4. -Average tumour size in this group.
17 19 21 23 25 27 29 31 33 35
Days
FIc. 7 (b).
120
110
100
90
80-
70-
60-
50-
40-
30-
20-
10-
37 39 41 43
. . . . . .632 H. J. G. BLOOM, C. E. DUKES AND B. C. V. MITCHLEY
Group 3. Cortisone, 1*25 mg. together with Provera 2.5 mg. three times
weekly to 6 animals from day 7.
Group 4. Provera, 2-5 mg. three times weekly to 6 animals from day 7,
Results.-Tumour grafts were successful in all 24 animals and in the controls
grew rapidly. Cortisone and Provera, alone or in combination, had no influence
whatsoever on this tumour (Fig. 8) and the experiment was terminated on day 20.
Transplanted Imferon Induced Sarcoma (CB 4460) in Male Hamsters (Experiment V)
EFFECT OF PROVERA, CORTISONE AND CORTISONE + PROVERA
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FIG. 8.-Administration of cortisone and cortisone together with Provera had no effect on a
non-renal transplanted tumour in the hamster (sarcoma C.B. 4460).HORMONE-DEPENDENT TUMOURS OF THE KIDNEY 633
Experiment VI
The transplantable hepatoma of the hamster, obtained originally from Dr.
Hadley Kirkman, was used in this experiment. This tumour also gives a high
proportion of successful takes and grows very rapidly.
Group 1. 4 control animals (transplanted tumours untreated with hormones).
Group 2. Cortisone, 1-25 mg. three times weekly to 4 animals from day 12
following transplantation.
Transplanted Hepatoma in Male Hamsters - (Experiment VI)
EFFECT OF PROVERA, CORTISONE AND CORTISONE + PROVERA
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FIG. 9.-Administration of cortisone and cortisone together with Provera had no effect on a
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Group 3. Cortisone, 1*25 mg. together with Provera 2-5 mg. three times
weekly to 4 animals from day 12.
Group 4. Provera, 2-5 mg. three times weekly to 4 animals from day 12.
Results.-Tumour grafts were successful in all 16 animals. As in the previous
experiment no difference was noted between the treated and control animals
(Fig. 9) and the experiment was terminated on day 26.
Experiment VII. (In conjunction with Dr. F. C. Chesterman)
Spontaneous renal tumours in the hamster have not been seen in this Labora-
tory nor by Dr. Kirkman at Stanford University. At the time of our experiments
the only other type of renal tumour reported in the hamster was that described
by Stewart et al. (1957) which was induced by a polyoma virus isolated from
Transplanted MHP Virus Induced Kidney Sarcoma (Experiment VII by Dr. F. C. Chesterman)
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leukaemic mouse tissue. Negroni et al. (1959) isolated a virus with similar pro-
perties from the spleen of an AK mouse with spontaneous lymphocytic leukaemia
(Mill Hill polyoma virus) and which, following inoculation into new born hamsters
and other rodents, produced a variety of tumours. In the hamster obvious
tumours were found most frequently in the kidney, heart and liver. Over 90
per cent of these animals developed renal tumours which began to appear as
early as 3 days after virus inoculation (Chesterman, 1961). These tumours are
rapidly growing, spindle cell sarcomas and can be serially transplanted.
At our request Dr. F. C. Chesterman of the Imperial Cancer Research Fund
Laboratories at Mill Hill studied the effect of administering cortisone to hamsters
Transplanted MHP Virus Induced Kidney Sarcoma (Experimenit VII by Dr. F. C. Chesterman)
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FIG. 10. (b) Inhibitiori of this tumour was achieved only with doses of cortisone which were toxic,
causing marked general weight loss and death of the host.
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bearing the transplanted Mill Hill polyoma virus renal tumour which was in its
thirty-fifth transfer generation. Twenty male golden hamsters from a colony
bred in the Imperial Cancer Research Fund Laboratory were treated with 5 mg.
of cortisone (Roussel) per 100 g. body weight subcutaneously on day 5, 7, 9 and 11
after tumour inoculation. With this dose no effect on tumour growth was obser-
ved (Fig. 10a). Because of the extremely rapid growth of the tumour the experi-
ment had to be terminated on day 13. During the period of observation the
animals showed no toxic effects. It was only in further experiments with more
prolonged cortisone treatment (5 mg. per 100 g. body weight on day 6, 8, 10, 12,
15 and 19) leading to marked general toxic effects associated with considerable
weight loss that tumour inhibition was noted (Fig. 10b). These animals had to be
killed at intervals soon after day 14, either because oflarge tumour size or marked
cortisone toxicity; the experiment was finally terminated on day 26. It would
appear that, during the short period of observation, cortisone, in doses tolerated
by the hamster, had no effect on the transplanted polyoma renal tumour.
Summary of Renal Tumour Histology in Hormone-Treated Hamsters
Transplanted adenocarcinomas in control hamsters and in those treated with
testosterone or Provera all showed signs of active proliferation with limited
central necrosis comparable to that found in untreated controls. On the other
hand, the tumours from animals treated with cortisone, alone or in combination
EXPLANATION OF PLATES
FIG. 11. (a) Multiple bilateral primary adenomatous tumours in the renal cortex of a
stilboestrol-treated male hamster.
(b and c) Unusually large multiple adenomas in the renal cortex of a male patient aged
51 in whom nephrectomy was carried out for chronic pyelonephritis.
FIG. 12.-(a) Mr. G. D. aged 64 (042760) multiple bilateral pulmonary metastases 2 months
following nephrectomy for adenocarcinoma of renal parenchyma. Solitary lung deposit
was present before operation.
(b) Radiological disappearance of all but two deposits in right lung, 8 weeks after com-
mencing treatment with Provera, 300 mg. daily by mouth. These deposits remained
stationary for 10 months and then slowly increased in size in spite of further treatment
with Provera, prednisone and finally testosterone.
FIG. 13. (a) Mr. D. W. aged 58: (040856), skeletal and intrathoracic metastases at time of
nephrectomy for adenocarcinoma of the renal parenchyma with invasion of the renal vein.
Pain and cachexia present 6 weeks post-operatively. Deterioration in general condition
together with increase in size of metastases in spite of treatment with oral Provera 300-500
mg. daily for 2 months.
(b) Striking improvement in general condition occurred within 2 months ofchanging from
Provera by mouth to testosterone proprionate by injection: skeletal and intrathoracic
metastases became smaller after 7 months treatment. Patient shown here after 18 months
testosterone therapy: 42 pounds gain in weight. Remained well on maintenance dose of
methyl testosterone 50 mg. daily sublingually with no evidence of active malignant disease
for 3 years after commencing hormone treatment. Recently, newmetastases have appeared.
(c) Osteolytic deposit in cranial vault increasing in size during Provera treatment.
(d) Healing of skull defect 18 months after changing from Provera to testosterone.
Histological proof of metastases obtained from tibial deposit.
FIa. 14. Mr. W. D. aged 59, (No. 049868), a recent case kindly referred by Sir Eric Riches:
Pulmonary metastases and a large fixed renal tumour which was initially treated by irradia-
tion. At laparotomy 4 weeks later renal mass still completely fixed and metastases seen
in liver and on diaphragm. Biopsy of secondary diaphragmatic nodule only performed-
renal adenocarcinoma. Pulmonary metastases increased in size and number and patient's
general condition deteriorated (a).
Five weeks after commencing provera, 300 mg. daily by mouth, the patient was improved.
Che3t X-ray showed disappearance of pulmonary metastases (b).
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with Provera, all showed extensive areas of necrosis and haemorrhage. In the
areas adjacent to necrosis reduced mitotic activity and varying degrees of tumour
cell degeneration, accompanied by an inflammatory reaction, were seen. Small
residual areas of viable-looking tissue remained, however, at the tumour peri-
phery in all these animals. Metastases were not observed in any of the treated
or control animals.
No histological difference was found between the tumours of treated and
untreated hamsters bearing either the transplanted C.B. 4460 sarcoma or the
transplanted hepatoma.
DISCUSSION
In the preceding experiments Provera and also testosterone had no effect on
the growth of the transplanted stilboestrol-induced renal tumour in the male
hamster. Cortisone, on the other hand, in moderate doses induced extensive
areas of tumour necrosis accompanied by a marked reduction in growth rate.
In general, the inhibitory effect of hormones upon experimental animal tumours
is cessation of further development, or merely reduction in growth rate. Well
marked regression of an established tumour is a rare event, and this has been our
experience with the hamster renal tumour. Some degree of regression, however,
was observed with prolonged cortisone treatment (Fig. 4 and 5).
Whereas progesterone inhibited the induction of the primary renal tumour by
stilboestrol and Professor Horning believed that Provera may inhibit the trans-
planted oestrogen-dependent tumour, the latter preparation, in doses of 2-5 mg.
two to three times weekly, in our experiments failed to influence the transplanted
oestrogen-independent growth.
The physiological and anti-tumour action of steroid substances are not neces-
sarily related, and small differences in molecular structure of closely allied com-
pounds may result in marked differences in the effects they produce. Thus,
although the physiological activity ofProvera is claimed to be many times greater
than that ofprogesterone in its action, for example, on endometrium, this may be
quite unrelated to its potency as an anti-tumour agent. We have not found any
reports in the literature concerning the effect of Provera on animal and human
tumours, but at the time of our hamster experiments we were also testing this
compound in patients with endometrial carcinoma, a tumour known to respond
in a proportion of cases to progesterone and to certain related synthetic prepara-
tions (Kelley and Baker, 1961 ; Stoll, 1961). So far we have seen an objective
response in one of 4 patients with advanced endometrial cancer treated with 300
mg. of Provera orally, daily (Bloom and Speed, 1963, unpublished observations).
In this patient there was complete disappearance of pulmonary metastases within
eight weeks of commencing treatment, and this has been maintained for eighteen
months.
In collaboration with Dr. F. J. C. Roe we are now investigating the effect of
Provera in doses larger than those employed in the animal experiments reported
here, and also of other progestational agents on the oestrogen-independent as well
as the oestrogen-dependent transplanted renal tumour. Provera in daily doses
of 0-625-2*5 mg. reduces growth rate and produces necrosis of the transplanted
tumour which is still dependent on oestrogen administration for its sustained
growth. Inhibition of the oestrogen-independent tumour was ultimately achieved
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with much larger doses of Provera (20 mg. and 40 mg. daily) than were used in
the present experiments.
The inhibitory effect of cortisone on the hamster renal tumour is not due to a
general toxic effect producing loss of body weight in the host. Furthermore, the
action ofthis hormone has some degree of specificity in that no such inhibition was
noted with the transplanted polyoma renal tumour in the hamster, nor on two
unrelated non-renal tumours in the same species. On the other hand, Crabb and
Kelsall (1951) found that cortisone acetate in doses of 0 15 mg./100 g. body weight
administered to male hamsters during a period preceding and followino grafting
caused growth retardation of quite a different tumour-a transplante1 lung
sarcoma.
A rapidly growing transplanted renal adenocarcinoma which arose sponta-
neously in a male hamster in 1957 has been carried on in serial transplants by
Fortner et al. (1961), and the effect on this tumour of various chemotherapeutic
agents and hormones, including cortisone, has been studied recently by Schabel
et al. (1961). No anti-tumour effect was observed with this hormone in doses up
to 35 mg. per kilogramme body weight per day for 7 days. The influence of
cortisone on 17 other different transplantable tumours in the hamster was also
studied. Marked inhibition was noted in only two examples, a melanoma and a
plasmacytoma. It would be of interest to study the influence of cortisone and
gonadal hormones on induced adenomatous renal tumours in other species such
as the one associated with lead acetate administration in the rat (Boyland et al.,
1962).
As with hormone dependent tumours in general, resistance may ultimately
develop in a tumour previously sensitive to cortisone (Lampkin and Potter, 1958).
We found no loss of inhibitory action of this hormone on the transplanted renal
tumour carried over five serial transplantations.
A combination of cortisone and Provera produced a greater suppression of
transplanted renal tumour growth than was achieved with cortisone alone (Fig.
6). This observation, which was confirmed in a second series of experiments, is
ofparticular interest in view of recent reports that a substance, chemically related
to progesterone, delta-l-testololactone (Fried et al., 1953), can potentiate the physio-
logical action of certain hormones, such as testosterone, in castrated immature
male mice (Lerner et al., 1960) and also the anti-tumour effect of cortisone in
mouse mammary tumours (Woolley, 1960). Delta-l-testololactone itself is physio-
logically inert, but possesses an anti-tumour effect on human breast cancer (Sega-
loff et al., 1960) and is derived from progesterone and other steroids by a process
of bio-synthesis. Experiments are being undertaken in this Laboratory to
investigate the effect of this substance, alone and in combination with other
hormone preparations, on the transplanted hamster renal tumour.
After six years of repeated transfer the hamster renal tumour is independent
of stilboestrol-pre-treatment of the host. Further experiments, reported in our
following paper (Bloom, Baker, Dukes and Mitchley, 1962), have shown that
bilateral adrenalectomy or castration inhibits this tumour. The effect is greater
with castration and can be nullified by the administration of either oestradiol
monobenzoate or testosterone proprionate. It is likely, therefore, that the trans-
planted renal tumour is still oestrogen-dependent, being maintained by endo-
genous oestrogen derived from the testis (Goldzicher and Roberts, 1952; Huggins
and Moulder, 1945) and from the adrenal. The action of testosterone can perhaps
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be explained by its conversion in the body to oestrogen (West et al., 1956;
Braun-Cantilo et al., 1962). On the other hand, attempts to substitute androgen
for oestrogen in the induction of renal tumours in male hamsters by implanting
30 mg. testosterone proprionate subcutaneously were not followed by the appear-
ance of renal tumours after 900 days observation (Kirkman, 1958).
Ghaleb (1961) found that tritium-labelled diethyl-stilboestrol was taken up
by renal tubular epithelium in the hamster and that the concentration of protein-
bound stilboestrol was significantly higher in males than in females. The action
of certain carcinogenic compounds may be related to their combination with
cellular protein in the target tissue. The tumour inhibitory action of cortisone
may, therefore, depend upon competition between this hormone and endogenous
oestrogen for combination with protein in tumour cells. A greater affinity for
cortisone may exclude oestrogen from these cells, leading either to their death or
to their increased differentiation. Our colleague, Dr. E. J. Ambrose (1960) has
found that the addition of cortisone in a concentration of 2 x 10-4 g./ml. to the
media in which hamster renal tumour cells are being cultured tends to restore to
these cells the structural features and the adhesive properties of the cellular
membrane found in normal renal epithelium. The cortisone LD50 for this tumour
was found to be three to four times lower than the value for normal hamster
renal epithelium.
In spite of the great difficulties generally encountered in trying to draw a
parallel between the behaviour of animal and human tumours, we are tempted
at this stage to speculate whether the induction and progress of the hamster renal
tumour and adenomatous tumour of the kidney in man have a comparable basis.
The origin of both tumours is closely related to renal tubules, and their macro-
scopic and histological appearances have a number of features in common.
One or more small adenomas are a common finding in the human kidney and
occasionally these progress to form multiple large tumours, the appearance
of which closely resembles that found in the stilboestrol-treated hamster (Fig.
1la, b, c). XVe have not seen adenocarcinoma nor multiple prominent adenomas
of the kidney in men following prolonged oestrogen administration for carcinoma
of the prostate, but proliferative cellular changes in the renal glomerular tufts
of such cases, similar to those seen in stilboestrol-treated guinea-pigs, have been
described by Trevan (1956). To produce renal tumours in man the duration of
oestrogen treatment would presumably have to extend over many years, since ini
the hamster such tumours do not appear until after 7 to 9 months' treatment which
represents approximately one-third of the animal's total life-span.
We have referred to the influence of various hormones, especially those of
gonadal origin on the normal kidney; to the role of the kidney itself as an endo-
crine organ producing " angiotensin" and " erythropoietin ", and also to reasons
for suspecting that renal adenocarcinoma in man, as in the hamster, may be
influenced by hormonal factors. Since hormones possess a marked degree of
tissue specificity and since their principal actions are fundamentally alike in all
species, knowledge gained from employing these substances in animal experiments
is worth exploring in man.
Since May 1959, 17 patients with metastases from adenocarcinoma of the
kidney have been treated with hormones at the Royal Marsden Hospital and this
work is to be the subject of a separate clinical report. In brief, there have been
three cases with pulmonary metastases which have shown an objective response
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to Provera and a further patient with skeletal deposits who responded quite
dramatically to testosterone, having first failed to improve with Provera (Fig. 13).
The response following testosterone in this case was maintained for over three
years. In other patients metastases have appeared to remain stationary for a
time or to progress more slowly since commencing or changing hormone therapy.
Caution in interpreting these observations is, of course, necessary since the
natural slow progress or actual regression of metastases are well-known features of
renal cancer in man (Miller et at., 1962; Gordon and Bateson, 1962). Partial or
complete spontaneous regression in human cancer, however, is an exceedingly
rare event. Everson and Cole (1956) were able to find only 47 authentic examples
of this phenomenon in the literature and by personal enquiry: only 2 of these
cases had hypernephromas. In cancer of the breast, a tumour of established
hormone dependency, there were no examples of spontaneous regression in 250
untreated cases studied by Bloom et at. (1962) and fluctuation in tumour growth
rate was noted in only one patient. Regression on disappearance of metastases
in the four cases of renal tumour referred to occurred within such a short time of
administering or changing the hormone preparation that it seemed likely that
the effect was related to treatment and not to a spontaneous event. Further
support for a therapeutic effect is found in the case showing regression of bone
metastases under testosterone therapy since, as far as we know, spontaneous
regression of skeletal deposits in this disease has not been reported. All examples
in the literature of spontaneous regression of renal adenocarcinoma have been in
relation to pulmonary deposits. Histological proof of metastases was obtained
in 3 of our 4 patients showing regression under hormone treatment. The fourth
patient died elsewhere and an autopsy was not performed.
It should be noted that whereas Provera and also testosterone each failed to
influence tumour growth in the present experiments with the transplanted ham-
ster renal tumour, the administration of these hormones to patients with meta-
static renal adenocarcinoma was associated with objective signs of tumour regres-
sion. In subsequent hamster experiments, however, Provera was found to
inhibit the stilboestrol-dependent strain of transplantable renal tumour and,
using much greater doses of this hormone, restraint of the "independent " growth
itself was finally achieved. So far, only those patients who have failed to respond
to Provera or to testosterone or who have escaped from such hormonal control,
have been treated with a cortico-steroid. Prednisone was used in a small number
of cases but so far no obvious tumour regression has been observed with this
preparation, although in the hamster cortisone produced marked regression of
the transplantable renal tumour. On the other hand, according to Kirkman
(1959) cortisone increased the incidence of primary kidney tumours in stilboestrol-
treated hamsters, and also favoured the development of metastases in stilboestrol-
treated hosts bearing transplanted tumours.
Human cancer that responds to changes in hormonal environment generally
arises in tissues which are normally under endocrine influence such as the breast,
thyroid, prostate and body of uterus. It would, therefore, be of great interest
if the development and progress of tumours of the human kidney eventually
proved to be related to the endocrine system. It is of additional interest that
the hormones concerned withrenaltumourinduction andinhibition in the hamster,
and associated with regression of metastatic cancer of the kidney in man, are of
sex origin.
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The bridge with which we have sought to span the experimental results in
hamsters, and the clinical observations in patients showing regression or reduced
growth rate of renal tumour metastases whilst receiving hormone therapy is
slender and more work needs to be done before one can speak of hormone-depen-
dency in human renal cancer. Further information concerning this question may
be obtained, for example, from the hormone excretion pattern in the urine of
patients with adenocarcinoma of the kidney before and after removal of the
primary tumour, when metastases appear and during hormone therapy. An
investigation of this type has been undertaken at the Royal Marsden Hospital
and attention is being given to oestrogen, 17-ketosteroid, 17-hydroxyketosteroid
and gonadotrophin excretion. More important, however, is the opportunity to
observe a larger number of cases under treatment and in the meantime this paper
is presented in the hope that other workers will now seek to test hormone-respon-
siveness in those patients with advanced carcinoma of the kidney for whom no
other treatment is practical.
SUMMARY
The development, natural history and pathological features of the oestrogen-
induced renal adenocarcinoma of the golden hamster reported originally by Dr.
Hadley Kirkman and by the late Professor E. Horning, have been reviewed.
The factors known to influence tumour induction and subsequent growth have
been described.
A series of new experiments are reported in which the effect of three hormone
preparations on tumour growth rate have been observed using the transplanted
renal tumour in young male hamsters. This tumour, in its 21st-35th generations,
progresses rapidly and is independent of exogenous oestrogen administration.
A synthetic oral progestational agent, 6-alpha-methyl-17-alpha-hydroxy-
progesterone acetate (Provera), in doses of 2.5 mg. subcutaneously three times
weekly, had no effect on tumour growth compared with untreated controls.
Testosterone proprionate in similar dosage also had no effect. On the other
hand, a marked inhibitory effect was seen in the tumours of those animals treated
with cortisone in doses of 1*25-2.5 mg. subcutaneously three times weekly, the
reduction in tumour growth rate being greater with the larger dose. This effect
was not dependent upon a general toxic manifestation in the last and, indeed,
appeared to have some specificity for the kidney tumour in that no changes were
observed with cortisone treatment in a transplanted polyoma kidney tumour, nor
in two unrelated non-renal tumours.
The most striking effect on the hamster renal tumour was achieved by a
combination of cortisone and Provera. These hormones together resulted in
practically complete inhibition of tumour growth, whereas Provera alone in the
same dosage, failed to bring about a tumour response. This observation, which
was confirmed in more recent experiments, is of interest because of the possible
hormone-potentiating effect of delta-l-testololactone, a substance related to pro-
gesterone, but physiologically inert.
Hormones possess a marked degree of tissue specificity and their principal
actions are fundamentally alike in all species. Chiefly because of this fact and
the existence of certain gross and mnicroscopic similarities between the adeno-
matous renal tumours of the hamster and adenoma and adenocarcinoma of the
human kidney, we have been tempted to consider that these animal experiments
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may shed light on the aetiology of renal carcinoma in man and point to a possible
new treatment for advanced cases.
Reference has been made to a clinical experiment being undertaken at the
Royal Marsden Hospital in which the effect ofhormone administration to patients
with disseminated renal adenocarcinoma (hypernephroma) is being studied. In
some cases objective signs of tumour inhibition or of actual regression have been
noted with Provera or testosterone and, at the present time, these observations
are considered more likely to be related to the endocrine treatmenit than to a
spontaneous event.
It is of interest that hormone dependent tumours in the hamster and possibly
in man may arise in the kidney, an organ which is not a recognised member of
the endocrine system nor a secondary sex organ. It is of additional interest
that the hormones concerned with primary renal tumour induction anid inhibition
in the hamster, and associated with regression of metastatic carcinoma of the
kidney in man, are ofsex origin. On the other hand, a renotropic action of certain
gonadal hormones has been known for many years following the original observa-
tions that castration and androgen administration influence kidney size in mice and
rats.
The kidney is a target organ for hormones other than growth hormone,
pitressin and corticosteroids and, by virtue of " angiotensin " and " erythro-
poietin " production, appears to have a role to play as an endocrine gland itself.
It is now suggested that a relationship may exist between hormonal factors and
the development and progress of the renal parenchymal adenoma and adeno-
carcinoma in man.
We are grateful to Professor Alexander Haddow for his interest in this work
and to Dr. Francis J. C. Roe for helpful advice in the preparation ofthe manuscript.
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